BCL2L11-BRAF Fusion FISH Probe
The BCL2L11-BRAF Fusion FISH Probe is used to confirm a fusion of the BCL2L11 and BRAF genes. The fusion of the BCL2L11 and BRAF genes has been associated with Thyroid Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| BCL2L11-BRAF-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-RERE | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-REOR | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-REGO | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-REGR | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-OROR | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-GORE | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-GROR | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| BCL2L11-BRAF-20-AQAQ | 20 (40 μL) | 200 μL |
|
BRAF Gene Summary
This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes. A pseudogene of this gene has been identified on the X chromosome. [provided by RefSeq, Aug 2017]
Gene Name: B-Raf Proto-oncogene, Serine/threonine Kinase
Chromosome: CHR7: 140433812 -140624564
Locus: 7q34
BCL2L11 Gene Summary
The protein encoded by this gene belongs to the BCL-2 protein family. BCL-2 family members form hetero- or homodimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. The protein encoded by this gene contains a Bcl-2 homology domain 3 (BH3). It has been shown to interact with other members of the BCL-2 protein family and to act as an apoptotic activator. The expression of this gene can be induced by nerve growth factor (NGF), as well as by the forkhead transcription factor FKHR-L1, which suggests a role of this gene in neuronal and lymphocyte apoptosis. Transgenic studies of the mouse counterpart suggested that this gene functions as an essential initiator of apoptosis in thymocyte-negative selection. Several alternatively spliced transcript variants of this gene have been identified. [provided by RefSeq, Jun 2013]
Gene Name: BCL2 Like 11
Chromosome: CHR2: 111878490 -111926022
Locus: 2q13
Gene Diseases
The BCL2L11 BRAF Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Thyroid Carcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|